Screening for ovarian cancer in the general population

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 20, Issue 2, 2006, Pages 307-320

  Chu, Christina S ^a   Rubin, Stephen C ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CA 125; Ovarian cancer; Population surveillance; Proteomics; Screening; Ultrasonography

Indexed keywords

ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 195 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CATHEPSIN L; CERULOPLASMIN; COLONY STIMULATING FACTOR 1; CYTOKERATIN 19 FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALACTOSYLTRANSFERASE; GELATINASE A; INHIBIN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; KALLIKREIN; MESOTHELIN; MONOCLONAL ANTIBODY; MUCIN LIKE CARCINOMA ASSOCIATED ANTIGEN; OSTEOPONTIN; PROTEASOME; PROTEIN P110; SIALIC ACID; TUMOR ANTIGEN;

CANCER MORTALITY; CANCER RESEARCH; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DISEASE MARKER; DOPPLER ECHOGRAPHY; EARLY DIAGNOSIS; ECHOGRAPHY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GYNECOLOGICAL EXAMINATION; HUMAN; MASS SCREENING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MORBIDITY; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; THREE DIMENSIONAL IMAGING; TRANSVAGINAL ECHOGRAPHY; UNITED KINGDOM;

AGED; CA-125 ANTIGEN; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; OVARIAN NEOPLASMS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33644893064     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2005.10.012     Document Type: Review

References (68)

1. M.S. Piver Prophylactic oophorectomy: Reducing the US death rate from epithelial ovarian cancer. A continuing debate The Oncologist 1 1996 326-330
2. A. Jemal T. Murray E. Ward et al. Cancer statistics, 2005 CA: A Cancer Journal for Clinicians 55 2005 10-30
3. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH consensus development panel on ovarian cancer. The Journal of the American Medical Association; 1995;273:491-7.
4. W. Burke M. Daly J. Garber et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer genetics studies consortium The Journal of the American Medical Association 277 1997 997-1003
5. J.M.G. Wilson G. Junger Principles and Practice of Screening for Disease 1968 World Health Organization Geneva
6. S.J. Skates D.E. Singer Quantifying the potential benefit of CA 125 screening for ovarian cancer Journal of Clinical Epidemiology 44 1991 365-380
7. Skates SJ, Jacobs IJ, MacDonald N, et al. Estimated duration of pre-clinical ovarian cancer from longitudinal CA125 levels. Proc Am Assoc Cancer Res; 1999. p. Abstract 288.
8. R.C. Bast Jr M. Feeney H. Lazarus et al. Reactivity of a monoclonal antibody with human ovarian carcinoma The Journal of Clinical Investigation 68 1981 1331-1337
9. R.C. Bast Jr T.L. Klug E. St John et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer The New England Journal of Medicine 309 1983 883-887
10. M. Nap Immunohistochemistry of CA 125. Unusual expression in normal tissues, distribution in the human fetus and questions around its application in diagnostic pathology The International Journal of Biological Markers 13 1998 210-215
11. S.E. Kabawat R.C. Bast Jr A.K. Bhan et al. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125 International Journal of Gynecological Pathology 2 1983 275-285
12. R.C. Bast Jr F.P. Siegal C. Runowicz et al. Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma Gynecologic Oncology 22 1985 115-120
13. V.R. Zurawski Jr R.C. Knapp N. Einhorn et al. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma Gynecologic Oncology 30 1988 7-14
14. N. Einhorn K. Sjovall R.C. Knapp et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer Obstetrics and Gynecology 80 1992 14-18
15. I.J. Jacobs S. Skates A.P. Davies et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: A prospective cohort study British Medical Journal 313 1996 1355-1358
16. I. Jacobs R.C. Bast Jr The CA 125 tumour-associated antigen: A review of the literature Human Reproduction 4 1989 1-12
17. R.P. Woolas F.J. Xu I.J. Jacobs et al. Elevation of multiple serum markers in patients with stage I ovarian cancer Journal of the National Cancer Institute 85 1993 1748-1751
18. K. Nustad R.C. Bast Jr T.J. Brien et al. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: First report from the ISOBM TD-1 workshop. International society for oncodevelopmental biology and medicine Tumour Biology 17 1996 196-219
19. T.J. O'Brien L.M. Raymond G.A. Bannon et al. New monoclonal antibodies identify the glycoprotein carrying the CA 125 epitope American Journal of Obstetrics and Gynecology 165 1991 1857-1864
20. P. Kenemans G.J. van Kamp P. Oehr et al. Heterologous double-determinant immunoradiometric assay CA 125 II: Reliable second-generation immunoassay for determining CA 125 in serum Clinical Chemistry 39 1993 2509-2513
21. K. Tamakoshi F. Kikkawa N. Hasegawa et al. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: Comparison with CA125 Gynecologic and Obstetric Investigation 39 1995 125-129
22. S.J. Skates F.J. Xu Y.H. Yu et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers Cancer 76 1995 2004-2010
23. S.J. Skates U. Menon N. MacDonald et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women Journal of Clinical Oncology 21 2003 206-210
24. S.J. Skates D.K. Pauler I.J. Jacobs Screening based on the risk of cancer calculation from bayesian hierarchical changepoint and mixture models of longitudinal markers Journal of the American Statistical Association 96 2001 429
25. C. van Haaften-Day Y. Shen F. Xu et al. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: A critical appraisal Cancer 92 2001 2837-2844
26. R.P. Woolas M.R. Conaway F. Xu et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses Gynecologic Oncology 59 1995 111-116
27. Z. Zhang S.D. Barnhill H. Zhang et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses Gynecologic Oncology 73 1999 56-61
28. C. Crump M.W. McIntosh N. Urban et al. Ovarian cancer tumor marker behavior in asymptomatic healthy women: Implications for screening Cancer Epidemiology, Biomarkers & Prevention 9 2000 1107-1111
29. E.J. Pavlik P.D. DePriest H.H. Gallion et al. Ovarian volume related to age Gynecologic Oncology 77 2000 410-412
30. S. Campbell V. Bhan P. Royston et al. Transabdominal ultrasound screening for early ovarian cancer British Medical Journal 299 1989 1363-1367
31. H. Hayashi Y. Yaginuma S. Kitamura et al. Bilateral oophorectomy in asymptomatic women over 50 years old selected by ovarian cancer screening Gynecologic and Obstetric Investigation 47 1999 58-64
32. A. Tabor F.R. Jensen J.E. Bock et al. Feasibility study of a randomised trial of ovarian cancer screening Journal of Medical Screening 1 1994 215-219
33. R. Millo M.C. Facca S. Alberico Sonographic evaluation of ovarian volume in postmenopausal women: A screening test for ovarian cancer? Clinical and Experimental Obstetrics & Gynecology 16 1989 72-78
34. J.R. van Nagell Jr P.D. DePriest M.B. Reedy et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer Gynecologic Oncology 77 2000 350-356
35. F.R. Ueland P.D. DePriest E.J. Pavlik et al. Preoperative differentiation of malignant from benign ovarian tumors: The efficacy of morphology indexing and Doppler flow sonography Gynecologic Oncology 91 2003 46-50
36. A.M. Sassone I.E. Timor-Tritsch A. Artner et al. Transvaginal sonographic characterization of ovarian disease: Evaluation of a new scoring system to predict ovarian malignancy Obstetrics and Gynecology 78 1991 70-76
37. J.P. Lerner I.E. Timor-Tritsch A. Federman et al. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system American Journal of Obstetrics and Gynecology 170 1994 81-85
38. E. Ferrazzi G. Zanetta D. Dordoni et al. Transvaginal ultrasonographic characterization of ovarian masses: Comparison of five scoring systems in a multicenter study Ultrasound in Obstetrics & Gynecology 10 1997 192-197
39. D. Timmerman T.H. Bourne A. Tailor et al. A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model American Journal of Obstetrics and Gynecology 181 1999 57-65
40. B.W. Mol D. Boll M. De Kanter et al. Distinguishing the benign and malignant adnexal mass: An external validation of prognostic models Gynecologic Oncology 80 2001 162-167
41. P.D. DePriest E. Varner J. Powell et al. The efficacy of a sonographic morphology index in identifying ovarian cancer: A multi-institutional investigation Gynecologic Oncology 55 1994 174-178
42. J.R. Carter M. Lau J.M. Fowler et al. Blood flow characteristics of ovarian tumors: Implications for ovarian cancer screening American Journal of Obstetrics and Gynecology 172 1995 901-907
43. A.C. Fleischer J.A. Cullinan D.M. Kepple et al. Conventional and color Doppler transvaginal sonography of pelvic masses: A comparison of relative histologic specificities Journal of Ultrasound in Medicine 12 1993 705-712
44. A.C. Fleischer W.H. Rodgers D.M. Kepple et al. Color Doppler sonography of ovarian masses: A multiparameter analysis Journal of Ultrasound in Medicine 12 1993 41-48
45. A. Kurjak M. Predanic S. Kupesic-Urek et al. Transvaginal color and pulsed Doppler assessment of adnexal tumor vascularity Gynecologic Oncology 50 1993 3-9
46. L.E. Timor-Tritsch J.P. Lerner A. Monteagudo et al. Transvaginal ultrasonographic characterization of ovarian masses by means of color flow-directed Doppler measurements and a morphologic scoring system American Journal of Obstetrics and Gynecology 168 1993 909-913
47. S.M. Stein S. Laifer-Narin M.B. Johnson et al. Differentiation of benign and malignant adnexal masses: Relative value of gray-scale, color Doppler, and spectral Doppler sonography AJR American Journal of Roentgenology 164 1995 381-386
48. L. Valentin Pattern recognition of pelvic masses by gray-scale ultrasound imaging: The contribution of Doppler ultrasound Ultrasound in Obstetrics & Gynecology 14 1999 338-347
49. A. Kurjak S. Kupesic T. Anic et al. Three-dimensional ultrasound and power doppler improve the diagnosis of ovarian lesions Gynecologic Oncology 76 2000 28-32
50. L.S. Cohen P.F. Escobar C. Scharm et al. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction Gynecologic Oncology 82 2001 40-48
51. S. Guerriero J.L. Alcazar S. Ajossa et al. Comparison of conventional color Doppler imaging and power doppler imaging for the diagnosis of ovarian cancer: Results of a European study Gynecologic Oncology 83 2001 299-304
52. I. Jacobs A.P. Davies J. Bridges et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography British Medical Journal 306 1993 1030-1034
53. G.L. Adonakis E. Paraskevaidis S. Tsiga et al. A combined approach for the early detection of ovarian cancer in asymptomatic women European Journal of Obstetrics, Gynecology, and Reproductive Biology 65 1996 221-225
54. M.H. Vuento U.H. Stenman J.P. Pirhonen et al. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer Gynecologic Oncology 64 1997 141-146
55. T.R. Holbert Screening transvaginal ultrasonography of postmenopausal women in a private office setting American Journal of Obstetrics and Gynecology 170 1994 1699-1703
56. S. Sato Y. Yokoyama T. Sakamoto et al. Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography Cancer 89 2000 582-588
57. J.R. Botkin K.R. Smith R.T. Croyle et al. Genetic testing for a BRCA1 mutation: Prophylactic surgery and screening behavior in women 2 years post testing American Journal of Medical Genetics 118A 2003 201-209
58. E.J. Pavlik T.L. Johnson II P.D. Depriest et al. Continuing participation supports ultrasound screening for ovarian cancer Ultrasound in Obstetrics & Gynecology 15 2000 354-364
59. M.A. Hasson R.M. Fagerstrom D.C. Kahane et al. Design and evolution of the data management systems in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial Controlled Clinical Trials 21 2000 329S-348S
60. R. Richter P. Schulz-Knappe M. Schrader et al. Composition of the peptide fraction in human blood plasma: Database of circulating human peptides Journal of Chromatography B Biomedical Science Applied 726 1999 25-35
61. E.F. Petricoin A.M. Ardekani B.A. Hitt et al. Use of proteomic patterns in serum to identify ovarian cancer Lancet 359 2002 572-577
62. B. Rockhill Proteomic patterns in serum and identification of ovarian cancer Lancet 360 2002 169 [author reply 170-1]
63. D.C. Pearl Proteomic patterns in serum and identification of ovarian cancer Lancet 360 2002 169-170 [author reply 170-1]
64. E.P. Diamandis Proteomic patterns in serum and identification of ovarian cancer Lancet 360 2002 170 [author reply 170-1]
65. M. Elwood Proteomic patterns in serum and identification of ovarian cancer Lancet 360 2002 170 [author reply 170-1]
66. I.J. Jacobs U. Menon Progress and challenges in screening for early detection of ovarian cancer Molecular & Cellular Proteomics 3 2004 355-366
67. F. Pettersson Annual Report on the Results of Treatment in Gynecological Cancer 1994 International Federation of Gynecology and Obstetrics Stockholm
68. R.C. Bast Jr Status of tumor markers in ovarian cancer screening Journal of Clinical Oncology 21 2003 200-205